Investigating how certain drugs can block the effects of the androgen receptor in advanced prostate cancer.
Official title: Mechanisms of Androgen Receptor Inverse Agonists in Advanced Prostate Cancer
Funded at Case Western Reserve University · NIH-10939509 · Data updated 2026-11-12
This study is looking at how certain new medications can help treat advanced prostate cancer, especially when other treatments aren't working anymore, to find better ways to slow down tumor growth and improve care for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | July 5, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $606,869 |
| NIH project number | 1R01CA291963-01 |
| Project ID | NIH-10939509 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adult males diagnosed with advanced prostate cancer, especially those who have developed resistance to androgen-deprivation therapy.
✕Less likely to help
Patients with early-stage prostate cancer or those who do not have androgen receptor involvement may not benefit from this research.
What this research studies
This research focuses on understanding the mechanisms by which androgen receptor inverse agonists can be used to treat advanced prostate cancer, particularly in cases where the cancer has become resistant to standard therapies. The study employs advanced molecular and computational biology techniques to explore how these drugs can alter the behavior of the androgen receptor and its associated gene expression. By using patient-derived xenograft models and cell lines that closely mimic the disease, the research aims to identify new therapeutic strategies that can effectively suppress tumor growth. Patients may benefit from insights gained into how to better target their cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for advanced prostate cancer, particularly for patients who have not responded to existing therapies.
How similar studies have gone: Previous research has shown promise in targeting androgen receptors in prostate cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Case Western Reserve University
Cleveland, United States Active
Researchers
- Principal investigator: Gryder, Berkley E — Case Western Reserve University
- Study coordinator: Gryder, Berkley E
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.